Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90

The article entitled, "Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90," which was published in the August 15, 2011, issue of Clinical Cancer Research (1), is being retracted at the request of Pfizer, the study sponsor.

In early 2016, the CCR editorial office became aware of potential image manipulation in the article through a record posted on pubpeer.com. The CCR editorial office contacted the corresponding author about the matter and received a response from a Pfizer representative, who informed us that the company assembled a review team to investigate the matter further. A Pfizer representative recently contacted the CCR editorial office with the results of the investigation: Most or all of the images in question appear to be duplications, and most of the authentic, original images that should have been used in place of the duplicated images cannot be located. As a result, Pfizer is requesting retraction of the article and has obtained consent from all six authors.

The matter was reviewed by members of the AACR Publications staff and the CCR editors, who agree that the figure manipulation present in the article merits retraction. Five authors have consented to this retraction notice; the CCR editorial office did not receive a response from Dr. Pramod P. Mehta.